A novel biodegradable microparticle development for the advanced drug delivery in angioplasty balloon

Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide, with balloon angioplasty playing a crucial role in restoring blood flow by compressing arterial plaques. Drug-coated balloons (DCBs) have enhanced angioplasty by delivering antiproliferative drugs like Paclitaxel to prevent restenosis. However, challenges such as uneven drug distribution, limited adhesion under blood flow, and premature drug washout still hinder their full potential. To address these limitations, we developed biodegradable microparticles using microfluidic techniques for controlled and sustained drug release. The microparticle fabrication process was optimized using experimental validation tests, refining parameters such as fluid viscosity, flow rates, and device geometry. Biocompatibility and platelet aggregation assays indicated promising safety profiles, though surface modifications are required to mitigate thrombogenicity. These microparticles, composed of biodegradable polymers, could gradually degrade in blood circulation, ensuring prolonged drug availability while minimizing inflammation and eliminating permanent implants. This system represents a significant advancement in angioplasty drug delivery, with potential to improve clinical outcomes by reducing restenosis rates and minimizing repeat interventions.